These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 30932219)
1. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. Pouillon L; Danese S; Hart A; Fiorino G; Argollo M; Selmi C; Carlo-Stella C; Loeuille D; Costanzo A; Lopez A; Vegni E; Radice S; Gilardi D; Socha M; Fazio M; González-Lorenzo M; Bonovas S; Magro F; Peyrin-Biroulet L Aliment Pharmacol Ther; 2019 May; 49(9):1181-1187. PubMed ID: 30932219 [TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. D'Amico F; Pouillon L; Argollo M; Hart A; Fiorino G; Vegni E; Radice S; Gilardi D; Fazio M; Leone S; Bonovas S; Magro F; Danese S; Peyrin-Biroulet L Dig Liver Dis; 2020 Feb; 52(2):138-142. PubMed ID: 31812570 [TBL] [Abstract][Full Text] [Related]
3. The nocebo effect: a clinical challenge in the era of biosimilars. Pouillon L; Socha M; Demore B; Thilly N; Abitbol V; Danese S; Peyrin-Biroulet L Expert Rev Clin Immunol; 2018 Sep; 14(9):739-749. PubMed ID: 30118338 [TBL] [Abstract][Full Text] [Related]
4. Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next? D'Amico F; Solitano V; Peyrin-Biroulet L; Danese S Expert Opin Biol Ther; 2021 Jan; 21(1):47-55. PubMed ID: 32857634 [TBL] [Abstract][Full Text] [Related]
5. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893 [TBL] [Abstract][Full Text] [Related]
6. To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars. Rezk MF; Pieper B Adv Ther; 2018 Jun; 35(6):749-753. PubMed ID: 29873005 [TBL] [Abstract][Full Text] [Related]
7. The nocebo effect challenges the non-medical infliximab switch in practice. Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188 [TBL] [Abstract][Full Text] [Related]
8. Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN. de Ridder L; Assa A; Bronsky J; Romano C; Russell RK; Afzal NA; Hauer AC; Knafelz D; Lionetti P; Strisciuglio C; Veres G; Winter H; Wolters VM; Sladek M; Vulto AG; Dias JA; J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):144-153. PubMed ID: 30169454 [TBL] [Abstract][Full Text] [Related]
9. [Biosimilars and the nocebo effect]. Braun J; Tsiami S; Buehring B; Kiefer D; Andreica I; Baraliakos X; Kiltz U Z Rheumatol; 2020 Apr; 79(3):267-275. PubMed ID: 31802197 [TBL] [Abstract][Full Text] [Related]
11. Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. Kristensen LE; Alten R; Puig L; Philipp S; Kvien TK; Mangues MA; van den Hoogen F; Pavelka K; Vulto AG BioDrugs; 2018 Oct; 32(5):397-404. PubMed ID: 30269270 [TBL] [Abstract][Full Text] [Related]
12. The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease. Pineles D; Malter L; Liang PS; Arsuaga A; Bosworth B; Hudesman DP; Chang S Eur J Clin Pharmacol; 2018 Oct; 74(10):1361-1362. PubMed ID: 29855655 [No Abstract] [Full Text] [Related]
13. Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases. Somers M; Bossuyt P; Ferrante M; Peeters H; Baert F J Crohns Colitis; 2020 Jun; 14(5):680-685. PubMed ID: 31875891 [TBL] [Abstract][Full Text] [Related]
14. The Clinical Implications of Nocebo Effects for Biosimilar Therapy. Colloca L; Panaccione R; Murphy TK Front Pharmacol; 2019; 10():1372. PubMed ID: 31849647 [TBL] [Abstract][Full Text] [Related]
15. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns? Gecse KB; Cumming F; D'Haens G Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783 [TBL] [Abstract][Full Text] [Related]
16. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. Avila-Ribeiro P; Fiorino G; Danese S Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114 [TBL] [Abstract][Full Text] [Related]
17. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors]. Jahnz-Rozyk K; Wiesik-Szewczyk E; Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192 [TBL] [Abstract][Full Text] [Related]
18. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. Macaluso FS; Leone S; Previtali E; Ventimiglia M; Armuzzi A; Orlando A; Dig Liver Dis; 2020 Nov; 52(11):1304-1309. PubMed ID: 32807691 [TBL] [Abstract][Full Text] [Related]
19. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice. Barbier L; Simoens S; Vulto AG; Huys I BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267 [TBL] [Abstract][Full Text] [Related]
20. Biosimilars in inflammatory bowel disease: ready for prime time? Gomollón F Curr Opin Gastroenterol; 2015 Jul; 31(4):290-5. PubMed ID: 26039720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]